Recent updates on GLP-1 agonists: current advancements and challenges
Choosing between these molecules depends on your study's primary endpoint: When to choose Retatrutide: Focus is on maximum weight loss efficacy
For context, the placebo group in the same trial lost only 2.4%, making the drug-attributable weight loss approximately 12.5 percentage points
[DOI] [PMC free article] [PubMed] [Google Scholar] 39.Wilding J.P.H., Batterham R.L., Calanna S., Davies M., Van Gaal L.F., Lingvay I., McGowan B.M., Rosenstock J., Tran M.T.D., Wadden T.A., et al
Contemporary OB-GYN: FDA approves-5-year-use-for-etonogestrel-implant-68-mg-contraceptive Safety Labeling Update for Nexplanon Patient Experiences with Nexplanon Summary of MedWatch Voluntary Reports for Nexplanon (240 reports of device complications for 1,577 reports submitted voluntarily, mainly by consumers) Rare Disease: FDA Approves First Treatment for Children With Menkes Disease The FDA approved the first-ever treatment for Menkes disease: Zydus Life Sciences Zycubo (copper histidinate) daily subcutaneous injection for pediatric patients
women should discuss existing NICE-approved options such as semaglutide (Wegovy) or tirzepatide (Mounjaro) with their GP
